Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2309 • 2019 ACR/ARP Annual Meeting
Clinical Study of Peripheral Blood Lymphocyte Subsets in Patients with Rheumatoid Arthritis Complicated with Osteoporosis
Ting Cheng¹, Sheng-xiao Zhang ², Xiao-qing Liu ¹, Jia Wang ¹, Chong Gao ³ and Xiao-feng Li ¹, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ²The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China (People's Republic), ³Brigham and Women’s Hospital, Harvard Medical School, Boston
Background/Purpose: Rheumatoid arthritis(RA) is an autoimmune disease mainly manifested by aggressive polyarthritis.The incidence of osteoporosis(OP) has risen and the risk of fracture has further increased…
Abstract Number: 2329 • 2019 ACR/ARP Annual Meeting
Do Myocardial Inflammation and Microvascular Dysfunction in RA Lead to Adverse Changes in Left Ventricular Structure and Function over Time? A Longitudinal Analysis of Participants from Rheumatoid Arthritis: Study of the Myocardium
Rabia Iqbal¹, Elizabeth Park ², Seitetsu Lee ³, Isabelle Amigues ⁴, Christopher Depender ², Afshin Zartoshti ², Jon Giles ⁵, Sabahat Bokhari ⁶ and Joan Bathon ⁵, ¹Division on Rheumatology, Columbia University, Philadelphia, PA, ²Division on Rheumatology, Columbia University, New York, NY, ³Division of Cardiology, Columbia University, New York, NY, ⁴National Jewish Health, Denver, CO, ⁵Division of Rheumatology, Columbia University, New York, NY, ⁶Division of Cardiology and Nuclear Cardiology Laboratory, Columbia University, New York, NY
Background/Purpose: The risk of developing heart failure (HF) in RA patients as compared with non-RA subjects is significantly higher even when adjusted for traditional cardiovascular…
Abstract Number: 2350 • 2019 ACR/ARP Annual Meeting
Derivation and Validation of a Biomarker-Based Cardiovascular Risk Prediction Score in Rheumatoid Arthritis
Jeffrey Curtis¹, Fenglong Xie ², Cynthia Crowson ³, Brent Mabey ⁴, Darl Flake ⁴, Richard Bamford ⁴, Cheryl Chin ⁴, Eric Sasso ⁵, Elena Hitraya ⁵, Alexander Gutin ⁴ and Jerry Lanchbury ⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, ³Mayo Clinic Rochester, Rochester, ⁴Myriad Genetics, Inc, South San Francisco, CA, ⁵Crescendo Bioscience, South San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) patients are at elevated risk for cardiovascular (CV) events, but efficient risk stratification based on CV prediction models is not part…
Abstract Number: 2375 • 2019 ACR/ARP Annual Meeting
Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports
Hiroaki Matsuno ¹, Tatsuya Atsumi ², Shuji Takei ³, Naoto Tamura ⁴, Masayoshi Harigai ⁵, Takao Fujii ⁶, Shigeki Momohara ⁷, Yuko Takahashi ⁸, Nobuhiro Narii ⁸, Naoto Tsujimoto ⁸, Atsushi Nishikawa ⁸, Taeko Ishii⁸, Kazuhiko Yamamoto ⁹, Masataka Kuwana ¹⁰ and Michiaki Takagi ¹¹, ¹Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ²Hokkaido University, Sapporo, Japan, ³Kagoshima University, Kagoshima, Japan, ⁴Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁵Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁶Wakayama Medical University, Wakayama, Japan, ⁷Hakkeikai Incorporated Medical Institution, Shizuoka, Japan, ⁸Eli Lilly Japan K.K., Kobe, Japan, ⁹Riken Center for Integrative Medical Sciences, Kanagawa, Japan, ¹⁰Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ¹¹Yamagata University Faculty of Medicine, Yamagata-shi, Japan
Background/Purpose: Baricitinib (bari), is an oral, selective inhibitor of Janus kinase (JAK) 1/ and JAK 2, is used to treat moderately to severely active RA…
Abstract Number: 2407 • 2019 ACR/ARP Annual Meeting
The Safety Profile of Upadacitinib in Japanese Patients with Rheumatoid Arthritis
Kunihiro Yamaoka¹, Yoshiya Tanaka ², Hideto Kameda ³, Barbara Hendrickson ⁴, Sebastian Meerwein ⁵, Ying Zhang ⁴ and Tsutomu Takeuchi ⁶, ¹Kitasato University School of Medicine, Kanagawa, Japan, Kanagawa, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Toho University, Tokyo, Japan, Tokyo, Japan, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, IL, ⁵AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁶Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Upadacitinib (UPA) is an oral reversible JAK inhibitor engineered for greater selectivity for JAK1 versus JAK2, JAK3, and TYK2, and is currently being assessed…
Abstract Number: 2825 • 2019 ACR/ARP Annual Meeting
Provider Variability in Glucocorticoid Prescribing for Patients with Rheumatoid Arthritis and Impact on Chronic Glucocorticoid Use
Michael George¹, Joshua Baker ², Lang Chen ³, Qufei Wu ², Fenglong Xie ⁴, Huifeng Yun ³ and Jeffrey Curtis ³, ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Birmingham
Background/Purpose: Glucocorticoids are recommended as short-term bridging therapy in patients with rheumatoid arthritis (RA), but as many as 30-40% of patients remain on glucocorticoids chronically.…
Abstract Number: 50 • 2019 ACR/ARP Annual Meeting
Circulating 25(OH)D, LL-37 and Antimicrobial Protein and Peptide (APP) Levels Are Altered Prior to Onset of Rheumatoid Arthritis
Vidyanand Anaparti¹, Xiaobo Meng ¹, Hemshekhar Mahadevappa ¹, Irene Smolik ¹, Neeloffer Mookherjee ¹ and Hani El-Gabalawy ¹, ¹University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Epidemiological studies suggest vitamin D deficiency as a potential risk factor for rheumatoid arthritis (RA) development, a chronic autoimmune disorder highly prevalent in indigenous…
Abstract Number: 183 • 2019 ACR/ARP Annual Meeting
Exploring Heterogeneity in Rheumatoid Arthritis: Patient Profiling Through Principal Component and Cluster Analysis of the BRASS Registry
Jeffrey Curtis¹, Michael Weinblatt ², Kenneth Saag ¹, Vivian Bykerk ³, Christina Charles-Schoeman ⁴, Stefano Fiore ⁵, Gregory St John ⁶, Toshio Kimura ⁷, Shen Zheng ⁵, Clifton Bingham ⁸, Grace Wright ⁹, Martin Bergman ¹⁰, Kamala Nola ¹¹, Daniel Furst ⁴ and Nancy Shadick ², ¹University of Alabama at Birmingham, Birmingham, AL, ²Brigham and Women's Hospital, Boston, MA, ³Hospital for Special Surgery, New York City, NY, ⁴University of California, Los Angeles, CA, ⁵Sanofi Genzyme, Bridgewater, NJ, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁷Regeneron Pharmaceuticals, Inc, Tarrytown, NY, ⁸Johns Hopkins University, Baltimore, MD, ⁹Private Practice, New York City, NY, ¹⁰Drexel University College of Medicine, Stockholm, Sweden, ¹¹Lipscomb University College of Pharmacy & Health Sciences, Nashville, TN
Background/Purpose: Data-driven principal component (PC) and cluster analysis has the potential to identify previously unknown patient subgroups within a rheumatoid arthritis (RA) registry to establish…
Abstract Number: 258 • 2019 ACR/ARP Annual Meeting
Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus
Geyanne Lui¹, Mangala Rajan ¹, Lisa Kern ¹, Laura Pinheiro ¹, Monika Safford ¹, Jeffrey Curtis ² and Iris Navarro-Millan ¹, ¹Weill Cornell Medicine, New York, ²University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Medicare beneficiaries who are disabled (coverage by the Social Security Disability Insurance (SSDI)) with rheumatoid arthritis (RA) and diabetes mellitus (DM) and under 65…
Abstract Number: 441 • 2019 ACR/ARP Annual Meeting
Multidimensional Health Assessment Questionnaire (MDHAQ) Scores in Spain vs USA: Similar Scores for Clinical Status and Self-report of Depression in Rheumatoid Arthritis (RA) but Poorer Scores for Both in Spondyloarthropathies (SpA) in Spain
Rosa Morlà¹, R. Castellanos ², Virginia Ruiz-Esquide ³, Julio Ramirez ⁴, Raimon Sanmarti ⁵, Jose Gomez-Puerta ⁵, Mariam Riad ⁶, Isabel Castrejon ⁶ and Theodore Pincus ⁶, ¹Rheumatology Unit, Xarxa Sanitaria Santa Tecla, Tarragona. Rheumatology, Fundacio Clinic, Barcelona, Barcelona, Spain, ²Fundacio Clinic. Hospital Clinic de Barcelona, Barcelona, Spain, ³Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁴Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ⁵Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Associations of depression with clinical status in RA1 and differences in clinical status in different countries2 have been reported. We compared MDHAQ (multidimensional health…
Abstract Number: 466 • 2019 ACR/ARP Annual Meeting
Predicting Risk of Radiographic Progression for Patients with Rheumatoid Arthritis
Thomas Huizinga ¹, Michael Weinblatt ², Nancy Shadick ², Cecilie Heegaard Brahe ³, Mikkel Østergaard ⁴, Merete Lund Hetland ⁵, Karen Hambardzumyan ⁶, Saedis Saevarsdottir ⁶, Megan Horton ⁷, Brent Mabey ⁸, Darl Flake ⁸, Alexander Gutin ⁸, Rotem Ben-Shachar ⁷, Eric Sasso ⁹ and Jeffrey Curtis¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²Brigham and Women's Hospital, Boston, MA, ³EuroSpA Coordinating Center, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Glostrup, Denmark, ⁴Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁵DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Myriad Genetics, Inc., Salt Lake City, UT, ⁸Myriad Genetics, Inc, South San Francisco, CA, ⁹Crescendo Bioscience, South San Francisco, CA, ¹⁰University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The multi-biomarker disease activity (MBDA) blood test has been shown to be a predictor of risk for radiographic progression in patients with rheumatoid arthritis…
Abstract Number: 503 • 2019 ACR/ARP Annual Meeting
A Pilot Phase 1, Randomized, Double-blind, Two-arm, Parallel Group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P17 and Humira in Healthy Male Subjects
Edward Keystone¹, Daniel Furst ², Malcolm Boyce ³, Frans van den Berg ³, SangJoon Lee ⁴, SungHyun Kim ⁴, YunJu Bae ⁴, GoEun Yang ⁴, JuHeon Koo ⁴, EunJin Choi ⁴ and Jonathan Kay ⁵, ¹Mount Sinai Hospital, Toronto, Canada, ²University of California, Los Angeles, CA, ³Hammersmith Medicines Research, London, United Kingdom, ⁴Celltrion Inc., Incheon, Republic of Korea, ⁵UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA
Background/Purpose: CT-P17 is a recombinant humanized monoclonal antibody that was developed as a biosimilar to the reference product, adalimumab. This was a first in human…
Abstract Number: 552 • 2019 ACR/ARP Annual Meeting
In the Real World Clinical Setting Etanercept Biosimilar SB4(BENEPAIL®) Demonstrates Equivalent Safety and Effectiveness in Biological Naïve as Well as with ENBREL® Pretreated RA,SPA, and PSA Patients
Herbert Kellner¹, ¹Praxis Prof. Herbert Kellner, Munich, Germany
Background/Purpose: Background: Biosimilar TNFα inhibitors have only become available in the last few years. Etanercept bisosimilar SB-4 Benepali® has been launched in March 2016 in…
Abstract Number: 921 • 2019 ACR/ARP Annual Meeting
Indicators of Actionable Levels of Atherosclerosis in RA Patients Who Appear to Have Low or Intermediate Atherosclerotic Cardiovascular Risk Based on Standard Risk Algorithms
Jon Giles¹, Cecilia Chung ², Mary Chester Wasko ³, Amy Kao ³, Annette Oeser ², C. Michael Stein ² and Joan Bathon ⁴, ¹Columbia University, Vagelos College of Physicians & Surgeons, New York, NY, ²Vanderbilt University, Nashville, TN, ³Allegheny Health Network-West Penn Hospital, Pittsburgh, PA, ⁴Division of Rheumatology, Columbia University, New York, NY
Background/Purpose: In the general population, statins reduces atherosclerotic cardiovascular disease (ASCVD) events in those with a computed tomography (CT)-assessed coronary artery calcium (CAC) score ≥100…
Abstract Number: 1081 • 2019 ACR/ARP Annual Meeting
Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Alexis Ogdie¹, Mei Liu ², Sabrina Rebello ², Angel Cronin ², Blessing Dube ², Robert McLean ², Esther Yi ³, Peter Hur ³ and Philip Mease ⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) share many clinical features but are differentiated by key clinical and molecular characteristics. Patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].